 "Lupin Pharma")
Shares of drug firm Lupin fell over 2% today after the company recalled more than 54,000 vials of anti-bacterial injection Ceftriaxone manufactured at its Mandideep facility in Madhya Pradesh due to violation of current good manufacturing norms.
After a weak opening, the stock slipped further to trade 2.27% lower at Rs 1,398 on BSE.
On NSE, it went down by 2.33% to Rs 1,397.40.
The ongoing voluntary recall is a class-III recall and is for the US and Puerto Rico, according to the latest enforcement report on the US Food and Drug Administration (US FDA) site.
The recall is being initiated by the company's US arm Lupin Pharmaceuticals Inc covering 54,472 vials of Ceftriaxone injection in various strengths, it added.
Citing reasons for the recall, the US FDA said "finished products manufactured (at Lupin Ltd's Mandideep plant were) using active pharmaceutical ingredients whose intermediates failed specifications".
The injection is used to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
